vimarsana.com

சிவப்பு ஆய்வகங்கள் லிமிடெட் ஆன் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Dr Reddy s to manufacture baricitinib for Covid -19 treatment in India

Read more about Dr Reddy s to manufacture baricitinib for Covid -19 treatment in India on Business Standard. Dr. Reddy s Laboratories announced that it has entered into a royalty-free, non-exclusive voluntary licensing agreement with Eli Lilly for the manufacture commercialisation of baricitinib in India

Dr Reddy s to manufacture Baricitinib drug for Covid treatment

Dr Reddy’s to manufacture Baricitinib drug for Covid treatment The drug baricitinib has received restricted emergency use approval from the CDSCO, for use in combination with Remdesivir for COVID-19 treatment. By IANS|   Updated: 12th May 2021 11:26 am IST entered into a royalty-free, non-exclusive voluntary licensing agreement for the same. (Photo: Company Logo) Hyderabad: Pharma major Dr. Reddy’s Laboratories Ltd on Wednesday announced that it has entered into a royalty-free, non-exclusive voluntary licensing agreement with Eli Lilly and Company for the manufacture and commercialization of Baricitinib in India. The drug baricitinib has received restricted emergency use approval from the Central Drugs Standard Control Organization (CDSCO), Ministry of Health, India, for use in combination with Remdesivir for the treatment of suspected or laboratory-confirmed COVID-19 in hospitalized adults requiring supplemental oxygen, invasive mechanical ventilation, or extracorporea

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.